Literature DB >> 6134820

Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292.

H J Smith, S E Halliday, D C Earl, D Stribling.   

Abstract

Six groups of four dogs were studied under pentobarbital anesthesia. Plasma levels of free fatty acids (FFA), glucose, insulin and lactate were measured after four challenges with isoproterenol (0.125 micrograms/kg/min i.v. for 10 min). In control animals, infusion of isoproterenol elevated plasma FFA, glucose, insulin and lactate, raised heart rate and lowered diastolic blood pressure. Propranolol lowered resting heart rate and blocked all the isoproterenol-induced responses. Atenolol (beta-1-selective antagonist) slowed resting heart rate and blocked FFA and heart rate responses. ICI 118,551 (beta-2-selective antagonist) blocked the glucose, insulin and lactate responses and the fall in diastolic blood pressure. Selectivity was lost at higher doses. ICI 141,292 (potent beta-1-selective antagonist and modest partial agonist) exhibited beta-1-selective blockade against both cardiovascular (heart rate) and metabolic (FFA) receptors. Partial agonist activity was also beta-1-selective, but there was no evidence of agonist activity at the metabolic receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134820

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

2.  Dose finding in angina--results with epanolol.

Authors:  T M Omland; C von Brandis; A M Abrahamsen
Journal:  Drugs       Date:  1989       Impact factor: 9.546

3.  Epanolol. A new once-daily antianginal agent: dose finding and long term efficacy.

Authors:  F Akhras; G Jackson
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 4.  Clinical pharmacology of epanolol. Pharmacodynamic aspects.

Authors:  J D Harry
Journal:  Drugs       Date:  1989       Impact factor: 9.546

5.  Immediate haemodynamic effects of a novel partial agonist, beta 1-adrenoceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and patients with ischaemic heart disease.

Authors:  J Bonde; T L Svendsen; K Lyngborg; J Mehlsen; J Trap-Jensen
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

6.  Effects on physical performance of intrinsic sympathomimetic activity (ISA) during selective beta 1-blockade.

Authors:  T Kullmer; W Kindermann; M Singer
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1987

7.  Central beta-adrenoceptors can modulate 5-hydroxytryptamine-induced tremor in rats.

Authors:  H Hallberg
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

8.  Assessment of the relative safety of the beta-blockers ICI 141,292 and atenolol in patients with bronchial asthma.

Authors:  S Groth; P Tønnesen; M Asted; H Dirksen; P G Sørensen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

10.  Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.

Authors:  P Omvik; P Lund-Johansen; H Haugland
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.